Acceptability and Tolerance Study of New Oral Nutritional Supplement

Aymes International Limited17 enrolled

Overview

* To evaluate tolerance and acceptability of AYMES ROME in patients requiring supplementary oral nutritional support compared with currently available alternatives. * To obtain data to support a submission to Advisory Committee on Borderline Substances (ACBS) for AYMES ROME (to allow for prescription in the community at National Health Service (NHS) expense).

To evaluate tolerance and acceptability of AYMES ROME in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference,convenience etc. To obtain data to support an ACBS submissions for AYMES ROME (to allow for prescription in the community at NHS expense).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Malnutrition

Interventions

AYMES ROMEDIETARY_SUPPLEMENT

AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (≥18 years) who are able to communicate their views regarding acceptability. * Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing approximately 300kcal/day * Patients expected to require oral nutritional supplementation for at least 2 further weeks. * Informed consent obtained. Exclusion Criteria: * Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study * Patients requiring a milk free diet * Patients with medical or dietary contraindication to any feed ingredients (see appendix 2 of protocol for full list) * Patients with significant renal or hepatic impairment * Patients with swallowing impairment requiring thickened fluids * Patients with inflammatory bowel disease or previous bowel resection.

Outcomes

Primary Outcomes

GI side effects when using AYMES Rome

Recording of absence/presence of any nausea, vomiting, abdominal pain, bloating / flatulence, when using AYMES Rome as assessed by presence / absence of side effect compared to baseline period

Time frame: 9 days

Secondary Outcomes

Change to bodyweight of subjects when using AYMES Rome

Recording of bodyweight (in kg) at start of study, start of intervention and end of intervention for comparison to investigate any trend in weight change during the intervention period compared to baseline

Time frame: 9 days

Compliance with prescription of AYMES Rome

Recording of amount of AYMES Rome consumed by subjects compared to amount prescribed. Good compliance = \>80% of prescribed being consumed. Same data collected for baseline product and compared with that of AYMES Rome

Time frame: 9 days

Bowel habits of subjects when using AYMES Rome - frequency

Recording of bowel habits whilst subjects consuming AYMES Rome, as assessed by frequency of bowel movements (number of stools per day) and compared to same data recorded during baseline period

Time frame: 9 days

Bowel habits of subjects when using AYMES Rome - stool consistency

Recording of bowel habits whilst subjects consuming AYMES Rome, as assessed by consistency of stools (assessed by Bristol Stool Chart) and compared to same data recorded during baseline period

Time frame: 9 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.